Table 4.

Treatment emergent adverse events (TEAEs) after a single dose of the test and reference formulations under fasting and fed conditions

AE	T, fasting		R, fasting		T, fed		R, fed
	nTEAE	n (%)	nTEAE	n (%)	nTEAE	n (%)	nTEAE	n (%)
Hypotension	26	18 (45)	21	15 (37.5)	9	7 (15.9)	7	5 (11.4)
Headache	0	0	1	1 (2.5)	0	0	0	0
Dizziness	1	1 (2.5)	1	1 (2.5)	0	0	0	0
Sinus tachycardia	1	1 (2.5)	0	0	0	0	0	0
Fever	1	1 (2.5)	1	1 (2.5)	0	0	0	0
Hypertriglyceridenmia	3	2 (5)	0	0	1	1 (2.3)	1	1 (2.3)
Leukocyturia	0	0	1	1 (2.5)	0	0	1	1 (2.3)
Blood bilirubin increased	0	0	0	0	0	0	1	1(2.3)
Creatine kinase increased	0	0	0	0	0	0	1	1 (2.3)
Hypophosphatemia	0	0	0	0	0	0	1	1 (2.3)
Atopic dermatitis	0	0	0	0	1	1 (2.3)	0	0
2nd degree Atrioventricular block	0	0	0	0	1	1 (2.3)	0	0
Anaemia	1	1 (2.5)	0	0	1	1 (2.3)	0	0